INHIBRX BIOSCIENCES INC (INBX) Fundamental Analysis & Valuation

NASDAQ:INBX • US45720N1037

69.3 USD
-4.2 (-5.71%)
At close: Mar 12, 2026
69.3 USD
0 (0%)
After Hours: 3/12/2026, 4:04:55 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This INBX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Taking everything into account, INBX scores 2 out of 10 in our fundamental rating. INBX was compared to 519 industry peers in the Biotechnology industry. INBX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. INBX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

2

1. INBX Profitability Analysis

1.1 Basic Checks

  • In the past year INBX has reported negative net income.
  • In the past year INBX has reported a negative cash flow from operations.
  • In the past 5 years INBX reported 4 times negative net income.
  • In the past 5 years INBX always reported negative operating cash flow.
INBX Yearly Net Income VS EBIT VS OCF VS FCFINBX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 950.90%, INBX belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • With an excellent Return On Equity value of 4582.06%, INBX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
ROA 950.9%
ROE 4582.06%
ROIC N/A
ROA(3y)268.02%
ROA(5y)139.35%
ROE(3y)153.62%
ROE(5y)40.8%
ROIC(3y)N/A
ROIC(5y)N/A
INBX Yearly ROA, ROE, ROICINBX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

  • INBX has a better Profit Margin (843786.00%) than 100.00% of its industry peers.
  • The Operating Margin and Gross Margin are not available for INBX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 843786%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INBX Yearly Profit, Operating, Gross MarginsINBX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 200K 400K 600K 800K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. INBX Health Analysis

2.1 Basic Checks

  • INBX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for INBX has been reduced compared to 1 year ago.
  • INBX has less shares outstanding than it did 5 years ago.
  • There is no outstanding debt for INBX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
INBX Yearly Shares OutstandingINBX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
INBX Yearly Total Debt VS Total AssetsINBX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • INBX has an Altman-Z score of -2.44. This is a bad value and indicates that INBX is not financially healthy and even has some risk of bankruptcy.
  • INBX's Altman-Z score of -2.44 is in line compared to the rest of the industry. INBX outperforms 46.63% of its industry peers.
  • INBX has a Debt/Equity ratio of 2.71. This is a high value indicating a heavy dependency on external financing.
  • With a Debt to Equity ratio value of 2.71, INBX is not doing good in the industry: 79.58% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 2.71
Debt/FCF N/A
Altman-Z -2.44
ROIC/WACCN/A
WACC9.07%
INBX Yearly LT Debt VS Equity VS FCFINBX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • A Current Ratio of 4.49 indicates that INBX has no problem at all paying its short term obligations.
  • The Current ratio of INBX (4.49) is comparable to the rest of the industry.
  • INBX has a Quick Ratio of 4.49. This indicates that INBX is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of INBX (4.49) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.49
Quick Ratio 4.49
INBX Yearly Current Assets VS Current LiabilitesINBX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. INBX Growth Analysis

3.1 Past

  • The earnings per share for INBX have decreased strongly by -108.39% in the last year.
  • The Revenue for INBX has decreased by -88.89% in the past year. This is quite bad
  • INBX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -56.75% yearly.
EPS 1Y (TTM)-108.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.72%
Revenue 1Y (TTM)-88.89%
Revenue growth 3Y-69.76%
Revenue growth 5Y-56.75%
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to decrease by -14.88% on average over the next years. This is quite bad
  • INBX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 319.07% yearly.
EPS Next Y-107.78%
EPS Next 2Y-42.87%
EPS Next 3Y-26.49%
EPS Next 5Y-14.88%
Revenue Next Year1200%
Revenue Next 2Y-41.42%
Revenue Next 3Y1400.52%
Revenue Next 5Y319.07%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
INBX Yearly Revenue VS EstimatesINBX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2027 2028 2029 2030 2031 100M 200M 300M
INBX Yearly EPS VS EstimatesINBX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 20 40 60 80 100

More info and screens

Find the best growth stocksShow best growing peers

0

4. INBX Valuation Analysis

4.1 Price/Earnings Ratio

  • INBX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year INBX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INBX Price Earnings VS Forward Price EarningsINBX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INBX Per share dataINBX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6 -8 -10

4.3 Compensation for Growth

  • INBX's earnings are expected to decrease with -26.49% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-42.87%
EPS Next 3Y-26.49%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. INBX Dividend Analysis

5.1 Amount

  • INBX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

INBX Fundamentals: All Metrics, Ratios and Statistics

INHIBRX BIOSCIENCES INC

NASDAQ:INBX (3/12/2026, 4:04:55 PM)

After market: 69.3 0 (0%)

69.3

-4.2 (-5.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)03-23
Inst Owners74.13%
Inst Owner Change20.74%
Ins Owners15.57%
Ins Owner Change0%
Market Cap1.01B
Revenue(TTM)200.00K
Net Income(TTM)1.69B
Analysts43.33
Price Target12.24 (-82.34%)
Short Float %18.69%
Short Ratio8.28
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.1%
Min EPS beat(2)-30.11%
Max EPS beat(2)34.31%
EPS beat(4)2
Avg EPS beat(4)0.63%
Min EPS beat(4)-30.11%
Max EPS beat(4)34.31%
EPS beat(8)4
Avg EPS beat(8)429.75%
EPS beat(12)4
Avg EPS beat(12)281.7%
EPS beat(16)6
Avg EPS beat(16)208.71%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5038.11
P/FCF N/A
P/OCF N/A
P/B 27.36
P/tB 27.36
EV/EBITDA N/A
EPS(TTM)-10.02
EYN/A
EPS(NY)-4.85
Fwd EYN/A
FCF(TTM)-9.87
FCFYN/A
OCF(TTM)-9.86
OCFYN/A
SpS0.01
BVpS2.53
TBVpS2.53
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 950.9%
ROE 4582.06%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 843786%
GM N/A
FCFM N/A
ROA(3y)268.02%
ROA(5y)139.35%
ROE(3y)153.62%
ROE(5y)40.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 2.71
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.8%
Cap/Sales 23.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.49
Quick Ratio 4.49
Altman-Z -2.44
F-Score3
WACC9.07%
ROIC/WACCN/A
Cap/Depr(3y)185.13%
Cap/Depr(5y)152.08%
Cap/Sales(3y)528.39%
Cap/Sales(5y)321.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-108.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.72%
EPS Next Y-107.78%
EPS Next 2Y-42.87%
EPS Next 3Y-26.49%
EPS Next 5Y-14.88%
Revenue 1Y (TTM)-88.89%
Revenue growth 3Y-69.76%
Revenue growth 5Y-56.75%
Sales Q2Q%N/A
Revenue Next Year1200%
Revenue Next 2Y-41.42%
Revenue Next 3Y1400.52%
Revenue Next 5Y319.07%
EBIT growth 1Y-51.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year72.68%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y14.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.18%
OCF growth 3YN/A
OCF growth 5YN/A

INHIBRX BIOSCIENCES INC / INBX FAQ

What is the fundamental rating for INBX stock?

ChartMill assigns a fundamental rating of 2 / 10 to INBX.


What is the valuation status for INBX stock?

ChartMill assigns a valuation rating of 0 / 10 to INHIBRX BIOSCIENCES INC (INBX). This can be considered as Overvalued.


What is the profitability of INBX stock?

INHIBRX BIOSCIENCES INC (INBX) has a profitability rating of 2 / 10.


Can you provide the financial health for INBX stock?

The financial health rating of INHIBRX BIOSCIENCES INC (INBX) is 4 / 10.


Can you provide the expected EPS growth for INBX stock?

The Earnings per Share (EPS) of INHIBRX BIOSCIENCES INC (INBX) is expected to decline by -107.78% in the next year.